RxDoctor Payments Data

Scott Corin, MD

Ophthalmology · N Dartmouth, MANPI 1962400911

Payments from drug & device makers

$16,682in general payments, 2019–2025

Across 32 payments — averaging $521.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$13K
  • Amgen$2K
  • Alcon Research LLC$1K
  • Glaukos Corporation$200
  • Alcon$191
  • Regeneron Healthcare Solutions, Inc.$140
  • plus $232 from 6 others

What the payments were for

  • Speaking & faculty fees$2,20074%
  • Food & beverage$77926%
  • Entertainment$100%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,682 in reported general payments places this provider in the 85th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$650,698
Medicare patients
1,645
Services billed
6,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast20$26,546
Prednisolone Acetate388$19,576
Latanoprost544$7,778
SimbrinzaBrinzolamide/Brimonidine Tart19$7,653
Ofloxacin315$5,036
RocklatanNetarsudil Mesylat/Latanoprost15$4,861
Diclofenac Sodium271$4,304
ErythromycinErythromycin Base382$3,957
Brimonidine Tartrate122$2,939
Timolol Maleate107$2,815
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat111$1,815
ValacyclovirValacyclovir Hcl32$1,294
Ketorolac Tromethamine56$1,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$191$7,65319 claims
Aerie Pharmaceuticals, Inc.Rocklatan$12,643$4,86115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in N Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →